Frequent mutations in SPOP occur in domains that interfere with E3 substrate binding and may affect SPOP's ability to degrade androgen receptors that contribute to cancer development in prostate cancer (An et al., 2014) and progesterone receptors in breast cancer cells (Gao et al., 2015). The gene discussed is SPOP; the disease is prostate carcinoma.